ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
[Predictors of short-term antimicrobial treatment outcomes in patients with liver failure complicated by spontaneous bacterial peritonitis: A retrospective study].
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSpontaneous bacterial peritonitis (SBP) is a common complication of liver failure and is associated with high mortality. This study aims to identify factors associated with the effectiveness of antimicrobial therapy in patients with liver failure complicated by SBP, thereby providing clinical evidence for individualized antibiotic selection.
methodsIn this retrospective study, the short-term antimicrobial treatment outcomes of 263 patients with liver failure complicated by SBP admitted to 2 tertiary teaching hospitals in China between 2015 and 2021 were analyzed. According to the initial antimicrobial regimen, patients were divided into three groups: the third-generation cephalosporin (TGC) group, the β-lactam/β-lactamase inhibitor combination group, and the carbapenem group. Based on short-term treatment outcomes, patients were further classified into an improvement group or a deterioration group. Baseline clinical characteristics (including age, sex, and etiologies of liver failure), changes in laboratory parameters before and after treatment (including complete blood count, liver function indices, and coagulation parameters), and short-term treatment outcomes (improvement or deterioration) were compared among the three antimicrobial treatment groups. Differences in baseline laboratory parameters between the improvement and deterioration groups were also analyzed. A binary Logistic regression model was established to identify independent factors associated with treatment outcomes, followed by subgroup analyses. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of these factors, and the area under the curve (AUC) and model prediction accuracy were calculated.
resultsA total of 263 patients were included, comprising 52 patients (19.8%) in the TGC group, 138 patients (52.5%) in the β-lactam/β-lactamase inhibitor combination group, and 73 patients (27.8%) in the carbapenem group. No significant differences were observed among the three groups regarding treatment outcomes or post-treatment biochemical parameters (all
conclusionsPTA and hemoglobin concentration are important predictors of short-term antimicrobial treatment outcomes in patients with liver failure complicated by SBP. Among these, PTA may provide useful guidance for the rational selection of antibiotics in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.